Introduction:

The recent advances in the management of multiple myeloma (MM) during the last years have included the autologous hematopoietic stem cell transplantation (auto-HSCT) to the treatment strategy of these patients.

Objective:

To present the first results in the "Hermanos Ameijeiras" hospital (HAH) with the application of auto-HSCT in patients with monoclonal gammopathies (MG) using high doses of melphalan (HD-Mel) as conditioning regimen (CR) and its impacton overall survival (OS).

Methods:

A retrospective study of all patients with MG who underwent auto-HSCT in the Hematology Service of the HAH in the period between 2009 and 2018 wasmade. The final sample comprised 14 cases.

Results:

The average age was 53.5 years; the majority had diagnosis of MM (85.7%) and all of them were diagnosed in stage III of Durie-Salmon; as CR 64.2% received HD-mel, at 200 mg/m2. The recovery of neutrophil and platelet counts occurred on average at 11.4 and 12 days respectively. Transplant related mortality (TRM) at day +30 was 7.1%. The probability of OS at 2 years was higher than 90% and at 5 years of 68%.

Conclusions:

It was verified that the performance of auto-HSCT with the use of HD-Mel as CR in patients with MG is a feasible procedure in our country with a relatively low TRM. It was possible to demonstrate that the inclusion of auto-HSCT in the treatment considerably improves the survival expectations of these patients.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )